Who are Basal insulin and exenatide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): insulin degludec + liraglutide, glargine + exenatide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/basal-insulin-and-exenatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Basal insulin and exenatide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Basal insulin and exenatide (Basal insulin and exenatide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Basal insulin + GLP-1 receptor agonist combination. Area: Diabetes.

phase 3 Basal insulin + GLP-1 receptor agonist combination Insulin receptor (basal insulin); GLP-1 receptor (exenatide) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Basal insulin and exenatide (Basal insulin and exenatide) — Mount Sinai Hospital, Canada. This combination uses basal insulin to provide background glucose control while exenatide stimulates insulin secretion and slows gastric emptying in response to meals.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Basal insulin and exenatide TARGET	Basal insulin and exenatide	Mount Sinai Hospital, Canada	phase 3	Basal insulin + GLP-1 receptor agonist combination	Insulin receptor (basal insulin); GLP-1 receptor (exenatide)
insulin degludec + liraglutide	insulin degludec + liraglutide	Hospital Universitario San Ignacio	marketed	Basal insulin + GLP-1 receptor agonist combination	Insulin receptor (degludec); GLP-1 receptor (liraglutide)
glargine + exenatide	glargine + exenatide	Huazhong University of Science and Technology	marketed	Basal insulin + GLP-1 receptor agonist combination	Insulin receptor (glargine); GLP-1 receptor (exenatide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Basal insulin + GLP-1 receptor agonist combination class)

Hospital Universitario San Ignacio · 1 drug in this class
Huazhong University of Science and Technology · 1 drug in this class
Mount Sinai Hospital, Canada · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Basal insulin and exenatide — Competitive Intelligence Brief. https://druglandscape.com/ci/basal-insulin-and-exenatide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab